Veraxa Biotech Holding AG — Form F-1/A

Veraxa Biotech AG (formerly Veraxa Biotech Holding AG), a Swiss biotech company, filed Form F-1 on August 5, 2026 to register resale of securities by selling securityholders. The company completed a SPAC merger with Voyager Acquisition Corp on June 10, 2026 (Closing Date). The F-1 registers: (i) 6,786,739 private warrants at USD 11.50 exercise price issued to Sponsor/underwriters; (ii) 12,650,000 public warrants also at USD 11.50; (iii) 120,295,385 existing common shares including 6,100,000 from SPAC class B conversion, 99,695,385 to directors/officers/affiliates, 3,500,000 to Cantor Fitzgerald, and 11,000,000 issuable under High Trail warrant agreements. Company has 141.4 million common shares outstanding post-merger with share capital of CHF 1,248,634 (par value CHF 100/11,325 per share). No material transaction details, valuations, or business metrics disclosed in legal opinion exhibits.